Nimbus Therapeutics

Nimbus Therapeutics is a clinical-stage biotechnology company based in Boston, Massachusetts, founded in 2009.

The company specializes in structure-based drug discovery, focusing on developing innovative small molecule medicines for challenging therapeutic areas, particularly those involving difficult-to-drug proteins linked to various human diseases. Nimbus employs advanced computational technologies and machine learning to enhance drug design and discovery processes. The company offers a range of drug discovery capabilities, including structure-based drug discovery, computational drug design, and machine learning-based predictive modeling. Nimbus is actively developing a pipeline of small molecule therapeutics targeting oncology, immunology, and metabolic diseases. Its notable projects include a clinical-stage HPK1 inhibitor for cancer treatment and a diverse preclinical portfolio addressing cancer, autoimmune conditions, and metabolic disorders. Nimbus collaborates with major pharmaceutical companies like Roche and Gilead Sciences to advance its drug development efforts.